Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data

Background and Aim: Drug sustainability (DS) is a surrogate marker for treatment efficacy. We aimed to compare the DS of two main biologics used to treat moderate-to-severe ulcerative colitis (UC), infliximab (IFX) and vedolizumab (VDZ), in a real-world setting. Methods: We conducted a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Konikoff, Tom, Yanai, Henit, Libchik, Dror, Avni-Biron, Irit, Snir, Yifat, Banai, Hagar, Broytman, Yelena, Dotan, Iris, Ollech, Jacob E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342318/
https://www.ncbi.nlm.nih.gov/pubmed/37445523
http://dx.doi.org/10.3390/jcm12134488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342318/
https://www.ncbi.nlm.nih.gov/pubmed/37445523
http://dx.doi.org/10.3390/jcm12134488

Ejemplares similares